Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Panbela Therapeutics Inc
PBLA
Healthcare
Biotechnology
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to...
induce polyamine metabolic inhibition (PMI). Flynpovi is a combination of CPP-1X (eflornithine) and sulindac. It has a dual mechanism of action whereby it suppresses the synthesis of new polyamines and increases the export and catabolism of polyamines from the diet and microbiome. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes metastatic castration-resistant prostate cancer, and STK-11 mutant NSCLC.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (OTCQB:PBLA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 17, 2023 6:00am
New Press Release - Panbela Announces Issuance of New Patent in Australia Patent is for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd. MINNEAPOLIS, July 17, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 10, 2023 8:16am
New Press Release - Panbela Announces Preliminary Safety Analysis for ASPIRE Trial
MMINNEAPOLIS, July 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase III...
read article.
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 28, 2023 8:39am
PBLA..... Spear-catching is sooooo much fun
Sub $2 again? Cheers !
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 28, 2023 8:15am
New Press Release - Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis
MINNEAPOLIS, June 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the SWOG Cancer Research Network’s PACES S0820 Phase III trial...
read article.
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 26, 2023 8:16am
PBLA....NR
Cheers !
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 26, 2023 8:15am
New Press Release - Panbela Announces Poster Presentation at the Endocrine Society Meeting: Polyamine Inhibition and β-Cell Preservation in Recent Onset Type 1 Diabetes
MINNEAPOLIS, June 26, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announces a poster presentation highlighting the results for CPP-1X...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 21, 2023 4:15pm
New Press Release - Panbela Announces Closing of Approximately $8.5 Million Public Offering
MINNEAPOLIS, June 21, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the closing of its previously announced public offering of (i) 2,270...
read article.
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 20, 2023 1:43pm
PBLA..... I'm back ; )
Lets get it on !!!!
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 16, 2023 8:15am
New Press Release - Panbela Announces Pricing of Approximately $8.5 Million Public Offering
MINNEAPOLIS, June 16, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the pricing of a public offering of (i) 2,270,000 shares of its...
read article.
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 13, 2023 12:48pm
PBL:A ....volume has literally dried up
That's the way these things go....or not ; )
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 13, 2023 11:12am
PBLA ..........stopped out
Wasn't fast enough to sell at the H.O.D On to greener pastures ; )
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Jun 13, 2023 10:06am
RE:PBLA ....has to hold $7.35
Oops ...pardon me.....I meant sub $7.....My bad Still holding my small position....Anything could still happen Cheers !
(0)
•••
NevaJones
X
View Profile
View Bullboard History
Post by
NevaJones
on Jun 13, 2023 9:57am
Tingo in Africa
Tingo Inc has been on the news for a wrong information sponsored by market manipulators to gain profit using short using distort strategy. But I'm thrilled that TIO keeps advancing
...more
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 13, 2023 9:46am
PBLA ....has to hold $7.35
Or it's back to sub - $6 JMHO
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 13, 2023 9:43am
PBLA ....Halted @ 6:41
C u in 5 mins
Prev
1
2
3
4
5
6
7
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.